Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Unknown 2 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 157 Neoplasms 115 Colorectal Neoplasms 97 Breast Neoplasms 90 Pancreatic Neoplasms 81 Leukemia, Myeloid, Acute 81 Recurrence 78 Neoplasm Metastasis 78 Prostatic Neoplasms 73 Melanoma 73 Ovarian Neoplasms 72 Multiple Myeloma 66 Stomach Neoplasms 60 Squamous Cell Carcinoma of Head and Neck 55 Lung Neoplasms 55 Triple Negative Breast Neoplasms 50 Glioblastoma 48 Lymphoma 47 Endometrial Neoplasms 43 Carcinoma, Hepatocellular 43 Advanced Solid Tumor 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 42 Lymphoma, Non-Hodgkin 41 Advanced Solid Tumors 37 Uterine Cervical Neoplasms 35 Small Cell Lung Carcinoma 35 Carcinoma, Renal Cell 34 Lymphoma, Large B-Cell, Diffuse 32 Lymphoma, B-Cell 32 Sarcoma 29

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × Ovarian Cancer Recurrent × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡